A Turning Point in Oncology: Mango Sciences and ImmunoACT Join Hands to Democratize CAR-T Therapy

Updated: December 08, 2025 22:44

Image Source: Facebook

Mango Sciences and ImmunoACT have launched a pioneering financing plan to make CAR-T therapy affordable in India. Using 0%-interest EMIs and value-based financial support — both covering up to ₹10 lakhs — the partnership aims to expand access to NexCAR19™, a locally developed CAR-T treatment for blood cancers across select hospitals.

The Breakthrough Story

A new collaboration between healthcare-AI firm Mango Sciences and gene-therapy pioneer ImmunoACT promises to transform access to cutting-edge cancer treatment in India. Their partnership introduces what they call the world’s first “bridge financing” and value-based payment plan for the revolutionary CAR-T therapy, making it financially viable for more patients battling blood cancers such as leukaemia and lymphoma.

Key highlights

Bridge financing with ease: Patients who receive ImmunoACT’s NexCAR19™ CAR-T therapy can now opt for 0%-interest EMI plans — covering up to ₹10 lakhs — to spread treatment costs over time.
Value-based offering: Clinically eligible patients may also qualify for value-based financial support — again up to ₹10 lakhs — reducing the immediate financial burden.
First-of-its-kind in the world: Together, Mango Sciences and ImmunoACT claim this is the global debut of a financing model for CAR-T therapy that blends clinical innovation with patient-centric affordability.
Targeted at blood cancers: The financing program applies to NexCAR19™, ImmunoACT’s India-developed CAR-T therapy approved for relapsed or refractory B-cell leukaemia and lymphomas — diseases where conventional treatment often fails.
Initial rollout in select hospitals: The programme will begin at a network of select healthcare facilities across India, giving early access to those who might otherwise be unable to afford CAR-T therapy.

The alliance seeks to marry the power of advanced immunotherapy with financial accessibility and patient-centric care. According to Mango Sciences’ CEO, the goal is to “use data science and technology to ensure patients can access the latest innovations in oncology.” ImmunoACT’s founder adds that the structure, being outcome-based, reflects their confidence in NexCAR19’s safety and efficacy.

If successfully scaled across India, this financing model could mark a turning point — lowering one of the biggest barriers to cutting-edge cancer treatment. Patients previously unable to afford CAR-T therapy may now have a viable route to a potentially life-saving treatment.

Sources: BusinessWire, The Tribune India, DigitalHealthNews, VOH Network.

Stay Ahead – Explore Now! CM Announces Major Investments: ₹23 Crore for State-of-the-Art Automated Lab, ₹11 Crore for Cutting-Edge Hostel Facility